Literature DB >> 30659925

Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo.

Min Mao1, Tao Zhang1, Zhuoying Wang1, Hongsheng Wang1, Jing Xu1, Fei Yin1, Gangyang Wang1, Mengxiong Sun1, Zongyi Wang1, Yingqi Hua2, Zhengdong Cai3.   

Abstract

Osteosarcoma (OS) is ranked as the most common primary bone malignancy in children and adolescents worldwide, and the 5-year overall survival rate of OS is not optimistic. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) has been implicated in tumor cell growth, proliferation, and anti-apoptosis in OS. Therefore, the discovery of novel molecular compounds that can effectively block STAT3 activation, is essential for the treatment of OS and improving prognosis. Here, we investigate whether Glaucocalyxin A (GLA), derived from Rabdosia japonica, exhibit the potential anticancer effects in OS. First of all, we identify that GLA potently suppressed cell proliferation, induced G2/M phase arrest and promoted substantial apoptosis in OS. Next, we conclude that GLA could induce Reactive oxygen species (ROS)-mediated oxidative stress via an imbalance of GSH and GSSG. Then, we elucidate for the first time that GLA could significantly inhibit both constitutive and IL-6-inducible activation of STAT3 (Tyr705) and JAK2, the upstream regulator of STAT3. Furthermore, we elucidate that the inhibition of STAT3 is mainly induced by ROS-mediated oxidative stress. Overall, our findings demonstrate that GLA could exhibit potent anticancer effects through effectively blocking the STAT3 signaling pathway, which was induced by ROS-mediated oxidative stress in OS in vitro and in vivo.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glaucocalyxin A; Osteosarcoma; Oxidative stress; ROS; STAT3

Year:  2019        PMID: 30659925     DOI: 10.1016/j.bbadis.2019.01.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  6 in total

Review 1.  STAT3 and its targeting inhibitors in osteosarcoma.

Authors:  Yun Liu; Shijie Liao; Samuel Bennett; Haijun Tang; Dezhi Song; David Wood; Xinli Zhan; Jiake Xu
Journal:  Cell Prolif       Date:  2020-12-31       Impact factor: 6.831

2.  Glaucocalyxin A Attenuates IL-1β-Induced Inflammatory Response and Cartilage Degradation in Osteoarthritis Chondrocytes via Inhibiting the Activation of NF-κB Signaling Pathway.

Authors:  Weidong Zhu; Yi Zhang; Yueshan Li; Hao Wu
Journal:  Dis Markers       Date:  2022-02-26       Impact factor: 3.434

3.  Glaucocalyxin A alleviates lipopolysaccharide-induced inflammation and apoptosis in pulmonary microvascular endothelial cells and permeability injury by inhibiting STAT3 signaling.

Authors:  Jianwei Cao; Meiling Liu; Shufang Feng; Yingying Li; Kaijun Zheng
Journal:  Exp Ther Med       Date:  2022-03-01       Impact factor: 2.447

4.  A novel strategy for the characterization of glaucocalyxin A metabolites in vivo and in vitro by UHPLC-Q-TOF-MS based on DDA and DIA data acquisitions.

Authors:  Wenjing Sun; Yiran Jin; Shuai Guan; Mengxin Yang; Miaoting Zhang; Jiali Hou; Yingfeng Du
Journal:  RSC Adv       Date:  2020-03-11       Impact factor: 4.036

5.  Glaucocalyxin A Inhibits the Malignancies of Gastric Cancer Cells by Downregulating MDM2 and RNF6 via MiR-3658 and the SMG1-UPF mRNA Decay Pathway.

Authors:  Yanqi Liu; Ping Chen; Daqing Qi; Linhui Chen
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

6.  Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway.

Authors:  Fei Jia; Yu Liu; Xinyu Dou; Chuanchao Du; Tianli Mao; Xiaoguang Liu
Journal:  Oxid Med Cell Longev       Date:  2022-01-25       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.